[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer (NCT02608216)

🧪 Interventions in This Study

• [18F]FLT (DRUG)
• PET/CT (DEVICE)
• ribociclib (DRUG)
• paclitaxel (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• University of Pennsylvania Hospital — Philadelphia, Pennsylvania

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Breast Neoplasm

• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer — Phoenix, Arizona
• Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer — Houston, Texas
• A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients — Aitkin, Minnesota
• MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC — Toronto, Ontario
• Improving Lifestyle Behavior by "Joven, Fuerte y Saludable" Multidisciplinary Program. — México,

Explore by condition: All Breast Neoplasm clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.